Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan

Tajiri, Yuji; Tsuruta, Munehisa; Ohki, Tsuyoshi; Kato, Tomoko; Sasaki, Yuko; Tanaka, Kayo; Kono, Shusuke; Tojikubo, Masayuki; Yamada, Kentaro

doi:10.1507/endocrj.ej11-0248

Cited by 26 publications

(29 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previous reports have suggested that sitagliptin has no effect on bodyweight, the cause of the weight gain in the present study might be due to inadequate diet and/or exercise therapy11. Indeed, Tajiri et al 24. reported that blood glucose levels were likely to increase over time in patients on sitagliptin therapy with low lifestyle scores, which is consistent with our present results.…”

Section: Discussionsupporting

confidence: 93%

Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea

Kubota

Yabe

Kanamori³

et al. 2014

J of Diabetes Invest

View full text Add to dashboard Cite

We analyzed the changes of glycemic control over 12 months and the factors influencing blood glucose in 162 Japanese patients with type 2 diabetes having inadequate glycemic control despite sulfonylurea‐based therapy who received add‐on sitagliptin. Hemoglobin A1c (HbA1c) decreased significantly after 4 weeks of treatment, and this improvement was maintained for 1 year, although HbA1c was slightly higher in week 52 than in week 24. Comparison of the patients showing a ≥0.4% increase of HbA1c between weeks 24 and 52 (n = 57) with the others (n = 105) showed a significant difference in the change of bodyweight, as well as the dose of glibenclamide (both P < 0.01). Although combined therapy with sitagliptin and a sulfonylurea seems to be effective for at least 1 year, blood glucose levels are more likely to increase again in patients who show greater weight gain after 24 weeks of treatment and those receiving a higher dose of glibenclamide.

show abstract

Section: Discussionsupporting

confidence: 93%

Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea

Kubota

Yabe

Kanamori³

et al. 2014

J of Diabetes Invest

View full text Add to dashboard Cite

show abstract

“…metformin, glyburide, and rosiglitazone) results in a particular cumulative incidence of monotherapy failure, which is termed secondary ineffectiveness (8). Tajiri et al reported the existence of secondary ineffectiveness in patients who received sitagliptin (23). On the other hand, another study reported that the effect of sitagliptin lasts for 60 weeks (24).…”

Section: Discussionmentioning

confidence: 99%

A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin Treatment

et al. 2015

View full text Add to dashboard Cite

Objective This retrospective study evaluated the long-term efficacy of sitagliptin and the factors contributing to its glucose-lowering effect. Methods Six hundred and sixteen dipeptidyl peptidase-4 inhibitor-naïve outpatients with type 2 diabetes who began sitagliptin treatment between December 1, 2009 and December 31, 2011 were included in this study. The inclusion criteria were that the patient had regularly visited our hospital for a period of ! 700 days from the initiation of sitagliptin treatment and the measurement of hemoglobin A1c (HbA1c) had been performed at 0, 3, 6, 12, 18, and 24 months after the initiation of treatment. From the population of 616 patients, 447 and 169 had received sitagliptin for ! 700 and <700 days, respectively. The primary endpoint was ΔHbA1c at 24 months. The factors associated with the hypoglycemic effect of sitagliptin were also investigated. Results Sitagliptin treatment significantly decreased the level of HbA1c, and the hypoglycemic effect was sustained for at least 2 years. The baseline HbA1c level, duration of diabetes, Δbody weight value, and ΔHbA1c value at 3 months were independently associated with the hypoglycemic effect of sitagliptin. Conclusion Sitagliptin has a long-term hypoglycemic effect in type 2 diabetes patients. A patient's ΔHbA1c at 3 months may be a predictor of their ΔHbA1c at 24 months.

show abstract

“…However, these results were based on data collected four months after discharge from our hospital; therefore, hospitalization may have influenced the effects of exenatide treatment. Furthermore, in some patients in whom the HbA1c levels initially decreased, relapse was reported after six months of DPP-4 inhibitor therapy (32). Further studies are essential in order to observe the long-term effects of exenatide over a longer period of time, such as a year.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of the Effects of Exenatide Administration in Patients with Type 2 Diabetes with Worsened Glycemic Control Caused by Glucocorticoid Therapy

et al. 2013

View full text Add to dashboard Cite

Glucocorticoid-induced hyperglycemia is common in patients with or without known diabetes mellitus. Exenatide, a glucagon-like peptide-1 receptor agonist, improves glycemic control without causing weight gain or hypoglycemia and is currently widely used in patients with type 2 diabetes mellitus. We herein report four cases of patients with type 2 diabetes with worsened glycemic control due to glucocorticoids who were successfully treated with exenatide administration.

show abstract

Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan

Cited by 26 publications

References 17 publications

Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea

Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea

A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin Treatment

Evaluation of the Effects of Exenatide Administration in Patients with Type 2 Diabetes with Worsened Glycemic Control Caused by Glucocorticoid Therapy

Contact Info

Product

Resources

About